Pursuant to Regulation 30 & 33 of SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of Nutraplus India Limited (the Company'') at it''s meeting held today, ....
Awaiting price reaction for this filing.
Nutraplus India Ltd, a single-segment Active Pharmaceutical Ingredient (API) manufacturer, submitted its audited financial results for Q4 and FY25 after a board meeting on July 15, 2025. The company reported a net loss of approximately ₹516 lakhs for FY25, slightly wider than the ₹501 lakh loss in FY24, with total expenses rising to ₹636 lakhs. An exceptional gain of around ₹107 lakhs partially offset the operating loss. The statutory auditor issued a Qualified Opinion, flagging that the company failed to comply with SEBI LODR timelines for submitting its limited review report and quarterly results. The company's balance sheet shows severely eroded equity of negative ₹53,902 lakhs as on March 31, 2025, against negative ₹53,000 lakhs a year earlier, meaning liabilities far exceed assets.
Negative for shareholders — the company is loss-making, has a deeply negative net worth indicating serious solvency concerns, and the auditor's qualified opinion over late regulatory filings raises governance red flags. This is a high-risk, distressed situation for retail investors.